Cart
sales@molnova.com
GRL-079
CAS No.
GRL-079 ( GRL079 )
Catalog No. M17094 CAS No.
GRL-079 is a novel potent, nonpeptidic HIV-1 protease inhibitor with 2.5-30 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGRL-079
-
NoteResearch use only, not for human use.
-
Brief DescriptionGRL-079 is a novel potent, nonpeptidic HIV-1 protease inhibitor with 2.5-30 nM.
-
DescriptionGRL-079 is a novel potent, nonpeptidic HIV-1 protease inhibitor with 2.5-30 nM against wild-type HIV-1NL4-3, 0.3-6.7 nM against HIV-2EHO, and 0.9-90 nM against laboratory-selected-PI-resistant HIV-1 and clinical HIV-1 variants resistant to multiple FDA-approved PIs (HIVMDR).
-
SynonymsGRL079
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number--
-
Formula Weight703.91
-
Molecular FormulaC34H49N5O7S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name(3R,3aS,4S,7aS)-3-(ethylamino)hexahydro-4H-furo[2,3-b]pyran-4-yl ((2S,3R)-4-((2-(cyclopropylamino)-N-isobutylbenzo[d]thiazole)-6-sulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Delino NS, et al. Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.02060-17.
molnova catalog
related products
-
Peptide T
Peptide T is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a synthetic octapeptide whose possible mechanism of action is the competitive inhibition of gp120 to the CD4 receptor as well as binding to vasointestinal peptide receptors and inhibiting cytokine action.
-
Elsulfavirine
Elsulfavirine is an HIV-1 infection reverse transcriptase inhibitor. It is a new anti-HIV drug.
-
Delavirdine mesylate
A potent HIV-1 reverse transcriptase inhibitor with IC50 of 0.26 uM for recombinant HIV-1 RT.
